GLOBAL PHARMA OUTSOURCING
360 ONE Asset acquires stake in OneSource Specialty Pharma
360 ONE Asset has acquired a stake in OneSource Specialty Pharma, a Contract Development and Manufacturing Organization (CDMO), for an undisclosed amount. The investment will support OneSource's innovation and global expansion plans. OneSource recently raised $95 million from other investors and is preparing to list its shares on stock exchanges.
Trump's 'America First' agenda may lead to higher tariffs on Indian auto, textiles, pharma: Experts
Indian exporters may face higher tariffs on goods like textiles and pharmaceuticals as Donald Trump's 'America First' agenda prioritizes protectionist measures. While this could negatively impact key Indian exports, a tougher stance on China might open new opportunities.
These large-caps have ¡®Strong Buy¡¯ & ¡®Buy¡¯ recos and an upside potential of more than 25%
Given market conditions these days, the chances are the bears will maul every stock on the street. But here¡¯s a lesson from history: When the market finally starts recovering, it will be led by stocks of good businesses with managements that have experience in dealing with all kinds of adversity. So, forget about the correction and how long it will last. Focus on what kind of business you are buying. ET Screener, powered by Refinitiv¡¯s Stock Report Plus, lists quality stocks with high upside potential over the next 12 months, having an average recommendation rating of ¡°Buy¡± or "Strong Buy". The screener applies different algorithms for all BSE and NSE stocks.
Strides Pharma's OneSource raises Rs 801 crore in pre-listing round
OneSource Specialty Pharma, an associate of Strides Pharma, secured Rs. 801 crore from investors including HBM Healthcare Investments and WhiteOak Capital. With these funds, OneSource will reduce debt and enhance its manufacturing capabilities. The company aims to list its shares by March 2025 and targets being debt-free by FY26. Strides shareholders will benefit significantly from this transaction.
India's global centre market to grow to $105 billion by 2030, says Nasscom-Zinnov report
India's global capability centres are projected to grow significantly, reaching a market size of $99 billion-$105 billion by 2030 from $64.6 billion in fiscal 2024. The growth is driven by the talent pool and increased multinational investments. The number of companies with GCCs in India is expected to rise to around 2,100-2,200 by 2030.
EQT set to acquire BPO GeBBS from ChrysCapital
Swedish private equity fund EQT is set to acquire Los Angeles-based healthcare BPO company GeBBS Healthcare Solutions for about $870 million. The deal, which outbid Hillhouse Investment, is expected to be signed soon. GeBBS, founded in 2005, employs 14,000 workers globally and competes with major firms like Wipro and IBM.
- Go To Page 1
Hillhouse bids highest to buy healthcare BPO GeBBS from Chrys Cap for $870 mn
GeBBS Healthcare Solutions, a Los Angeles-based healthcare BPO firm, is nearing acquisition by Hillhouse Investment, which has offered about $870 million. The final decision is expected in two weeks as ChrysCapital holds another round of negotiations. The acquisition will potentially see industry veterans Gautam Barai and Gautam Narayan at the helm.
As the Indian economy grows, a new definition of defensive stocks is required? 8 stocks from 2 sectors with upside potential up to 31%
On two significant days, first the election results on June 4th and second, last Monday, when there was a sharp sell off in global markets, on both the days, while Nifty and broader market was under severe pressure, it was FMCG stocks, which were able register gains. Explanation was the same old, that money is moving to defensive stocks. While moving to defensive stocks trade which has been taking place for some time. But there is a fundamental question. Given the fact that the Indian economy has changed and new sectors have emerged, whose growth is better and also stable, should FMCG stocks be considered defensive stocks ? The reason why it is important to understand this is the fact that over the next few quarters volatility might be high and there will be phases where this defensive stock trade might come and one should be prepared for it. Also their numbers are clearly indicating that time to make a shift has come.
Sanofi looking to expand India hub with Rs 3.6k-cr push
The Hyderabad GCC will support Sanofi's global operations spanning commercial, manufacturing, supply chain research and development (R&D) and digitalisation. The GCC in India will help the company bring some of outsourced functions in-house, giving it more control over critical operations like manufacturing, commercial and R&D.
Carlyle, CVC & Hillhouse in the fray for GeBBS
Global private equity firms including Carlyle Group, Hillhouse Investment and CVC Capital Partners have been shortlisted to acquire ChrysCapital-owned GeBBS Healthcare Solutions, said people familiar with the development. The deal proposes to value the Los Angeles-based healthcare business process outsourcing firm at $800 million. The firms, shortlisted after the initial round, will submit a binding offer by mid-July, said one of the persons, who did not wish to be identified.
Better to own a set of stocks from the digital ecosystem rather than betting on one stock? 15 stocks with upside potential of upto 48%
Few day¡¯s back there was an issue with the telecom provider and the services stopped for some time. Now which would be the companies which got impacted the most, the telecom service provider, the answer is no. As a customer one would not get any reduction in the monthly billing because services were down for some time. The companies which may have got impacted would be a platform company on which one orders food, such as a swiggy or zomato. The reason, in the peak time of demand, a customer is not able to order food online due to internet service being down, that demand will not come back when the internet is back. But the other platform company which sells insurance was also not impacted. The reason is, if one was planning to buy an insurance policy and there is no internet, the demand will get postponed not get extinguished. The digital ecosystem is making things simple but it is yet complicated when it comes to investing.
Payoneer Elevate empowers 500+ service export SMBs on their global expansion journey
Payoneer Elevate 2024 marked the 8th edition of Payoneer¡¯s global flagship event in India, empowering entrepreneurs, founders, and growth leaders of service export businesses on their journey towards global expansion. Held on April 18, 2024, in the capital city, Payoneer Elevate 2024 delivered domain-focused knowledge sessions for over 500 Indian Small- and Medium-sized Businesses (SMBs) aiming for global growth. Here's how Payoneer is leading the transformation of cross-border payments to support Indian SMB exports.
View: Overturn cultural practices and dogmas to spur our companies to spend on R&D
WhatsApp showcases tales of ancient glory, while global reports highlight India's rankings in hunger, press freedom, and sustainable development. India ranks 40th on the GII 2023, above all BRICS nations except China.
Defensive stocks: FMCG is ¡°passe¡±; 8 stocks from two sectors may be called ¡°new defensives¡± with upside potential of up to 32%
1994 to 2024 is a difference of 30 years, but there is one thing which has remained constant, advice to move to defensive stocks when markets are volatile or there is an event risk. Four questions need to be asked; first, what is a defensive stock? Second, is a stock which was considered a defensive in 1994 when the Indian economy was just opening, still a defensive stock in 2024 ? Third, should there be a new definition of defensive stock in 2024 ? Last but not the least, what are the new defensive sectors or stocks?
Indegene looking forward to enhancing EBITDA & PAT margins: Management
Indegene's growth plans post IPO include sustaining EBITDA margin growth, retiring loans, and active acquisitions. The company aims to enhance tech capabilities, expand globally, and focus on key markets to support customers worldwide.
Indegene IPO booked over 10x so far on Day 3. Check subscription, GMP and other details
Indegene IPO GMP: On the final day of the initial public offer (IPO), Indegene was booked a little over 10 times so far on Wednesday, the last day of the bidding process.
Indegene IPO booked over 4x so far on Day 2. Check subscription, GMP and other details
Indegene's IPO oversubscribed 4 times on the second day, led by non-institutional investors; QIB portion least subscribed.
Indegene IPO fully subscribed on Day 1. Check subscription, GMP and other details
On the first day of bidding, the initial public offering (IPO) of Indegene Ltd received a steady response, primarily fueled by strong interest from non-institutional investors (NII).
Why Kenneth Andrade is going contra, avoiding defence and PSU stocks
Kenneth Andrade, of Old Bridge Capital Management, emphasizes market breadth narrowing to specific stocks and commodity favoritism. He discusses challenges in the IT and defense sectors, PSU companies, and future businesses like Zomato and Paytm. Andrade says: "I am a firm believer that any company out there who gets pricing power will get price earning multiples. "
Who will get D-Street's vote: Stocks to benefit from a BJP win in polls
"The BJP manifesto has a strong positive read-through for Indian equities," said Seshadri Sen, head of research at Emkay Global Financial Services. "Railways, defence, housing mortgages, tourism, and aviation are direct beneficiaries; while textiles and pharma API are probable winners."
Chrys Capital looks to sell GeBBS at $1b valuation
ChrysCapital, the largest homegrown PE fund, is looking to sell GeBBS Healthcare Solutions, about six years after acquiring the Los Angelesbased healthcare business process outsourcing (BPO) company, said multiple people aware of the development. A potential deal is likely to value GeBBS at $800 million to $1 billion, the people said.
Hot Stocks: Brokerage view on Infosys, HDFC Bank, Piramal Pharma and Indigo
Nomura neutral on HDFC Bank at Rs 1625 target price. Kotak Mahindra Bank raises InterGlobe Aviation's target to Rs 4200. UBS maintains Infosys buy at Rs 1800. Jefferies bullish on Piramal Pharma.
India's healthcare care innovation market to double to $60 billion by FY28, says new report
The report outlines the opportunity in healthcare innovation where companies increasingly leverage emerging technologies to add innovation vectors¡ªincluding new business models, software-led solutions, and products¡ªthat extend beyond more longstanding value engineering considerations.
From fake American accents to AI, Indian BPO sector has come a long way
Call it Outsourcing 2.0, which can take India from once being the telemarketing voice of American companies to becoming in near future their very brains. A far cry from early captive units of American MNCs in India, the GCCs have now embedded themselves deeper within business functions, moving up the value chain to deliver higher-value processes.
Indian drug manufacturers benefit from Big Pharma interest beyond China
China has for nearly 20 years been the preferred location for a range of pharmaceutical research and manufacturing services due to the low cost and speed offered by contract drugmakers there.
Here's why Pankaj Tibrewal is bullish on the power sector
?There are those challenges and that is clearly reflected in the daily price of power if you look at. If you look at the IEX numbers, the power cost is at two, two-and-a-half rupees.
For risk takers: 5 midcap stocks which have seen an improvement in score have potential upside of up to 59%
The Nifty continues to form a new high every day, more number of mid-caps stocks are joining the party. Stocks from sectors like speciality chemical, agro chemical and services sector are making it to the list. ET screener powered by Refinitiv¡¯s Stock Report Plus applies different algorithms & filters to all BSE and NSE stocks, and lists stocks which fulfill the various criteria as specified into the algorithms & filters to find those which might help navigate the stock market.
Despite the run-up, Reliance continues to be nicely balanced: Gurmeet Chadha
¡°It has been a while since Reliance Industries consolidated. The earnings were pretty strong. The O2C segment did pretty well while Jio continues and retail continues to get more traction. Also, the demerger of Jio Financial Services was another small trigger and the market was valuing it at about Rs 200-220.
Pharma CMOs may feel heat as USFDA approves fewer new drugs, GlobalData report says
Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, stated GlobalData in its latest report - ¡®New Drug Approvals and Their Contract Manufacture ¨C 2023 Edition¡¯. The report said that USFDA¡¯s new molecular entity approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop, which meant fewer commercial-scale production contracts for the most innovative products.
Load More
